Pricing Log in Create free account
Saturday 17 October 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.

218.01 18.49 −7.82%
Market cap
$94.4B
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Moderna, Inc. (MRNA) Debt to equity

Alert me on Debt to equity

Moderna, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.1×, up 0.0× from fiscal 2025 (0.1×). Over the past ten years it has ranged from 0.0× (fiscal 2016) to 0.1× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.1× 1,858.33%
FY2024 0.0× (91.33%)
FY2023 0.0× (13.00%)
FY2022 0.0× 12.77%
FY2021 0.0× (1.63%)
FY2020 0.0× 30.70%
FY2019 0.0× 52.31%
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period Debt to equity Change
Jun 2026 0.1× 8.48%
Mar 2026 0.1× 15.46%
Dec 2025 0.1× 2,417.86%
Sep 2025 0.0× (17.65%)
32 more quarters

Against its own ten years

Low 0.0× High 0.1×
Ten-year median 0.0×
Current reading's percentile 100

Debt to equity against peers

Company Debt to equity
ROIV Roivant Sciences Ltd. compare 0.0×
VRTX Vertex Pharmaceuticals Incorporated compare 0.0×
ARGX argenex SE compare 0.0×
REGN Regeneron Pharmaceuticals, Inc. compare 0.1×
MRNA Moderna, Inc. 0.1×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 0.2×
RVMD Revolution Medicines, Inc. compare 0.4×
ALNY Alnylam Pharmaceuticals, Inc. compare 0.7×
RPRX Royalty Pharma PLC compare 0.9×
Biotechnology industry median 0.0×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on MRNA